Pressemitteilungen

Finnish home sleep apnea testing innovation receives well deserved attention at World Sleep 2022 in Rome

Nukute’s technology and home sleep apnea testing (HSAT) solution received serious interest from the global community of sleep physicians and other experts in the field of sleep medicine. The World Sleep 2022 conference held in Rome March 11-16 was the 16th iteration of the World Sleep Congress arranged annually by the Minnesota-based World Sleep Society.Nukute had a strong presence at the...

Global medical technology leader Matti E. Lehtonen appointed CEO of Nukute

Matti brings to Nukute a wealth of experience in medical technology and building and managing businesses and organisations with global reach. Matti joins us after 14 years with GE Healthcare where he served as the General Manager of GE's global Anesthesia and Respiratory Care business, and from 2016 also as the Chairman of the Board of GE Healthcare Finland. Prior to GE, Matti worked in a variety...

The City of Oulu outsources sleep apnea screening to medtech company Nukute

Nukute’s service solution, powered by Nukute’s own CE-marked medical device innovation, facilitates a healthcare process that leads to a reduced need for specialised health care. The cost effectiveness the device and solution provides unequivocally helped seal the deal with the City of Oulu.   The decision was made in collaboration with the previous service provider, the University Hospital of...

Timo Hildén appointed Nukute’s Chairman of the Board of Directors

The Finnish medtech start-up renewed its Board to strengthen its strategic competence in dealing with the global medtech market. Nukute’s Board received a total of three new members. Alongside Hildén, Mr. Tommi Mäkelä as the representative of the Pharmacy Pension Fund (Finland) and Mr. Frans Wuite, CEO of Kompassi Gmbh. Johannes Gullichsen, Pekka Virtanen and Timo Laitinen continue as old...

Finnish medtech company Nukute successfully closes its series A funding round and goes after COVID-19 – receives a strategic three million euro investment from the Pharmacy Pension Fund (Finland)

Medtech company Nukute raised funding of €4.1 million on its series A round, €4.9 million with public funding included. The single largest investment came from the Pharmacy Pension Fund (Finland), that believed in Nukute’s business with an investment of €3.0 million. The company is moving forward with clinical trials and the obtaining of the CE marking for the added functionality to the Nukute...